According to a press release on the official website of Altria Group, Inc. on June 26th, Altria has announced that it has submitted a Pre-Market Tobacco Product Application (PMTA) to the Food and Drug Administration (FDA) for its on! PLUS oral nicotine pouch product. The application was submitted by Altria's wholly-owned subsidiary, Helix Innovations LLC (Helix).
Helix has submitted PMTA for three different flavors of on! PLUS: tobacco, mint, and wintergreen. Each flavor has three different nicotine strength options.
The CEO and General Manager of Helix, Nick MacPhee, stated that...
Helix's submission of the on! PLUS application demonstrates Ochia's commitment to meeting consumers' ever-changing preferences through innovative products that have the potential to reduce risks. We believe that on! PLUS is a groundbreaking product and, once authorized by the FDA, will make a significant contribution to Helix's growth in the US market.
Paige Magness, Senior Vice President of Ochia Client Services LLC, stated that...
We have long believed that providing authorized smoke-free products for adult tobacco consumers is beneficial. We believe that these PMTAs demonstrate that responsibly selling on! PLUS can offer an attractive alternative in the market.
In order to obtain market authorization for PMTA, manufacturers must demonstrate that the marketing of new tobacco products is for the protection of public health. This requires the FDA to consider the risks and benefits for the overall population, including tobacco product users and non-users, as well as adolescents. on! PLUS is a product of Helix, and following authorization, it is expected that these products will be distributed by Altria Group Distribution Company (AGDC).
Currently, Helix is selling on! nicotine pouches in the United States. In the first quarter of 2024, on! saw a 32% year-on-year increase in shipments and reached a retail market share of 7.1% in the entire oral tobacco category in the United States.
We welcome news tips, article submissions, interview requests, or comments on this piece.
Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn
Notice
1. This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.
2. The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.
3. This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.
4. Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.
Copyright
This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.
For copyright-related inquiries, please contact: info@2firsts.com
AI Assistance Disclaimer
This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.
We welcome any corrections or feedback. Please contact us at: info@2firsts.com
